Streamlining urine drug testing workflow

Phenomenex has introduced Strata-X-Drug B Plus, a solid-phase extraction (SPE) sample preparation product for urine drug testing in clinical and forensic toxicology. An expansion of Phenomenex’s drug testing product line, the new Drug B Plus option joins the original Strata-X-Drug B, which is designated for matrices such as plasma, whole blood and serum.

 

The new Drug B Plus product features Phenomenex’s Solvent Shielding Technology, which enables an enzyme hydrolysis to be carried out directly in the microplate well, reducing transfer steps, time requirements and cost. And the hydrolysis solution can be held for six hours or more, providing flexibility in protocol planning. 

To meet the throughput demands of high-volume drug testing laboratories, Strata-X-Drug B Plus is available in 96-well plate format. The product ensures high recoveries, low variation, time savings and reduced solvent requirements, and its protocol eliminates conditioning and equilibration steps from traditional SPE methods. The new sorbent enables extraction of more than 22 drugs of abuse.

www.phenomenex.com

 

 

 

Other news

Upcoming Events

Update Course in Gynaecological Cytology

London Regional Cytology Training Centre, Level 6X, St Marks Building, Watford Road, Harrow HA1 3UJ
12-14 December 2018

Managing Cultural Differences in the Workplace

The Holiday Inn - Kensington Forum, 97 Cromwell Road, London SW7 4DN
21 January 2019

British Society for Haematology Paediatric Symposium

Royal College of Paediatrics and Child Health, 5-11 Theobalds Road, London WC1X 8SH
14 February 2019

Challenges in the clinical biochemistry laboratory and beyond

The Royal College of Pathologists
28 February 2019

British Society for Haematology 59th Annual Scientific Meeting

SEC Glasgow
1-3 April 2019

Latest Issue

Pathology In Practice

Pathology In Practice

Dec 2018

Molecular diagnostics and LAMP technology

Register now to apply for regular copies of Pathology In Practice and free access to premium content, as well as our regular newsletters.